Performance of Spectral CT-scan in Patients With Metastatic Colorectal Cancer: a Prospective Multicentre Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: CT Images.
- Who it may be relevant to
- Registry conditions: Colo-rectal Cancer. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Spectral CT is a rapidly expanding imaging modality that allows a reduction in iodine dose and irradiation compared to conventional scanning. It uses the difference in attenuation of the material according to the two different energy levels of the incident x-ray beams. The dual-energy scanner has a wide range of clinical applications, particularly in abdominal imaging.
Detailed description
First of all, the virtual creation of mono-energy images between 40 and 140 keV has shown subjective and objective improvement of tumor detection of hypovascular lesions using low energies (40keV). It has been shown to be of interest in vascular and cardiac imaging, and to reduce artefacts in bone imaging. However, its performance in oncology analysis has been little studied. The selection of patients for peritoneal and hepatic carcinosis surgery is fundamental, as surgery allows a prolongation of survival, but are associated with a non-negligible morbi-mortality rate.
Spectral CT provides improved detection of peritoneal carcinosis and liver metastases of colorectal cancer compared to conventional CT acquisition.
Interventions
- Other CT Images
Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer
Primary outcome measures
- Comparison of peritoneal lesion mapping between spectral scanning and conventional scanning [Time frame: Year : 1]
- Comparison of hepatic lesion mapping between spectral scanning and conventional scanning [Time frame: Year : 1]
Secondary outcome measures (2)
- Evaluation of response to chemotherapy in RECIST 1.1 [Time frame: Year : 1]
- Evaluation of response to chemotherapy in Radiomics [Time frame: Year : 1]
Eligibility criteria
Inclusion criteria
- Patients followed for colorectal cancer with synchronous or metachronous liver metastases and/or peritoneal carcinosis
- Patients with a curative surgical resection plan
Exclusion criteria
- Patients with non-metastatic colorectal cancer
- Patients treated with chemotherapy without surgical plans
- Patients with colorectal cancer with extra-hepatic and extra-peritoneal metastases alone (e.g. lung, bone)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- CHU Saint-Etienne — Saint-Etienne
Identifiers
NCT: NCT06024837 · IRBN1162022/CHUSTE